224 related articles for article (PubMed ID: 34379047)
21. Spectrum of disease outcomes in mice infected with YFV-17D.
Erickson AK; Pfeiffer JK
J Gen Virol; 2015 Jun; 96(Pt 6):1328-1339. PubMed ID: 25646269
[TBL] [Abstract][Full Text] [Related]
22. A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies.
Mishra N; Boudewijns R; Schmid MA; Marques RE; Sharma S; Neyts J; Dallmeier K
mBio; 2020 Apr; 11(2):. PubMed ID: 32265332
[TBL] [Abstract][Full Text] [Related]
23. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.
Tretyakova I; Nickols B; Hidajat R; Jokinen J; Lukashevich IS; Pushko P
Virology; 2014 Nov; 468-470():28-35. PubMed ID: 25129436
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.
Martins MA; Bonaldo MC; Rudersdorf RA; Piaskowski SM; Rakasz EG; Weisgrau KL; Furlott JR; Eernisse CM; Veloso de Santana MG; Hidalgo B; Friedrich TC; Chiuchiolo MJ; Parks CL; Wilson NA; Allison DB; Galler R; Watkins DI
PLoS One; 2013; 8(1):e54434. PubMed ID: 23336000
[TBL] [Abstract][Full Text] [Related]
25. A Sensitive Yellow Fever Virus Entry Reporter Identifies Valosin-Containing Protein (VCP/p97) as an Essential Host Factor for Flavivirus Uncoating.
Ramanathan HN; Zhang S; Douam F; Mar KB; Chang J; Yang PL; Schoggins JW; Ploss A; Lindenbach BD
mBio; 2020 Apr; 11(2):. PubMed ID: 32291299
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development.
Franco D; Li W; Qing F; Stoyanov CT; Moran T; Rice CM; Ho DD
Vaccine; 2010 Aug; 28(35):5676-85. PubMed ID: 20600494
[TBL] [Abstract][Full Text] [Related]
27. YF17D-based vaccines - standing on the shoulders of a giant.
Sanchez-Felipe L; Alpizar YA; Ma J; Coelmont L; Dallmeier K
Eur J Immunol; 2024 May; 54(5):e2250133. PubMed ID: 38571392
[TBL] [Abstract][Full Text] [Related]
28. Specialized
Li D; Lu HT; Ding YZ; Wang HJ; Ye JL; Qin CF; Liu ZY
J Virol; 2023 Apr; 97(4):e0194922. PubMed ID: 37017533
[TBL] [Abstract][Full Text] [Related]
29. Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo.
de Freitas CS; Higa LM; Sacramento CQ; Ferreira AC; Reis PA; Delvecchio R; Monteiro FL; Barbosa-Lima G; James Westgarth H; Vieira YR; Mattos M; Rocha N; Hoelz LVB; Leme RPP; Bastos MM; Rodrigues GOL; Lopes CEM; Queiroz-Junior CM; Lima CX; Costa VV; Teixeira MM; Bozza FA; Bozza PT; Boechat N; Tanuri A; Souza TML
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007072. PubMed ID: 30699122
[TBL] [Abstract][Full Text] [Related]
30. A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain.
Thibodeaux BA; Garbino NC; Liss NM; Piper J; Blair CD; Roehrig JT
Vaccine; 2012 May; 30(21):3180-7. PubMed ID: 22425792
[TBL] [Abstract][Full Text] [Related]
31. Vaccination with Replication Deficient Adenovectors Encoding YF-17D Antigens Induces Long-Lasting Protection from Severe Yellow Fever Virus Infection in Mice.
Bassi MR; Larsen MA; Kongsgaard M; Rasmussen M; Buus S; Stryhn A; Thomsen AR; Christensen JP
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004464. PubMed ID: 26886513
[TBL] [Abstract][Full Text] [Related]
32. Identification of Novel Yellow Fever Class II Epitopes in YF-17D Vaccinees.
Mateus J; Grifoni A; Voic H; Angelo MA; Phillips E; Mallal S; Sidney J; Sette A; Weiskopf D
Viruses; 2020 Nov; 12(11):. PubMed ID: 33198381
[TBL] [Abstract][Full Text] [Related]
33. Vaccine and Wild-Type Strains of Yellow Fever Virus Engage Distinct Entry Mechanisms and Differentially Stimulate Antiviral Immune Responses.
Fernandez-Garcia MD; Meertens L; Chazal M; Hafirassou ML; Dejarnac O; Zamborlini A; Despres P; Sauvonnet N; Arenzana-Seisdedos F; Jouvenet N; Amara A
mBio; 2016 Feb; 7(1):e01956-15. PubMed ID: 26861019
[TBL] [Abstract][Full Text] [Related]
34. A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses.
Oreshkova N; Myeni SK; Mishra N; Albulescu IC; Dalebout TJ; Snijder EJ; Bredenbeek PJ; Dallmeier K; Kikkert M
Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960238
[TBL] [Abstract][Full Text] [Related]
35. Dynamic viral dissemination in mice infected with yellow fever virus strain 17D.
Erickson AK; Pfeiffer JK
J Virol; 2013 Nov; 87(22):12392-7. PubMed ID: 24027319
[TBL] [Abstract][Full Text] [Related]
36. Construction and characterization of a recombinant yellow fever virus stably expressing Gaussia luciferase.
Kassar TC; Magalhães T; S JVJ; Carvalho AGO; Silva ANMRD; Queiroz SRA; Bertani GR; Gil LHVG
An Acad Bras Cienc; 2017; 89(3 Suppl):2119-2130. PubMed ID: 28746549
[TBL] [Abstract][Full Text] [Related]
37. Visualization of a neurotropic flavivirus infection in mouse reveals unique viscerotropism controlled by host type I interferon signaling.
Li XF; Li XD; Deng CL; Dong HL; Zhang QY; Ye Q; Ye HQ; Huang XY; Deng YQ; Zhang B; Qin CF
Theranostics; 2017; 7(4):912-925. PubMed ID: 28382163
[TBL] [Abstract][Full Text] [Related]
38. Pathophysiologic and transcriptomic analyses of viscerotropic yellow fever in a rhesus macaque model.
Engelmann F; Josset L; Girke T; Park B; Barron A; Dewane J; Hammarlund E; Lewis A; Axthelm MK; Slifka MK; Messaoudi I
PLoS Negl Trop Dis; 2014; 8(11):e3295. PubMed ID: 25412185
[TBL] [Abstract][Full Text] [Related]
39. Structure of the yellow fever NS5 protein reveals conserved drug targets shared among flaviviruses.
Dubankova A; Boura E
Antiviral Res; 2019 Sep; 169():104536. PubMed ID: 31202975
[TBL] [Abstract][Full Text] [Related]
40. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
